ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "MicroRNA"

  • Abstract Number: 954 • 2017 ACR/ARHP Annual Meeting

    Microrna-21 Is a Critical Regulator of Autoimmunity through Promoting Effector and Metabolic Function of Pathogenic TH17 Cells

    Xiang Yu1 and Nan Shen1,2,3, 1Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, and Shanghai Jiao Tong University, Shanghai, China, 2Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine and Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China, 3Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease that causes mortality and morbidity worldwide. Recent studies suggest proinflammatory TH17 cells are key pathogenic…
  • Abstract Number: 972 • 2017 ACR/ARHP Annual Meeting

    JAK/STAT Mediated Inhibition of Mir-23a~24-2~27a Cluster Potentiates Activation of CD14+ Monocytes in Treatment-Resistant RA

    Marina Frleta-Gilchrist, Donna McIntyre, Aziza Elmesmari, Lynn Stewart, Derek Baxter, Mariola Kurowska-Stolarska, Derek Gilchrist and Iain B. McInnes, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: While emerging and existing treatments of RA allow better options and clinical outcomes for patients, studies informing drug resistant states and further clinical therapeutic…
  • Abstract Number: 1009 • 2017 ACR/ARHP Annual Meeting

    Novel Non-Coding RNAs Associated with Rheumatoid Arthritis in Asians By Gene-Based Testing

    Aleksander Lenert1 and David W. Fardo2, 1Internal Medicine, Div. of Rheumatology, University of Kentucky, Lexington, KY, 2Biostatistics, College of Public Health, University of Kentucky, Lexington, KY

    Background/Purpose: Rheumatoid arthritis (RA) is a complex genetics disease driven by multiple genetic contributors as evidenced by association with over 100 risk SNPs by GWAS.…
  • Abstract Number: 1336 • 2017 ACR/ARHP Annual Meeting

    Unique Role for miR429 in RA and Acute Model of Arthritis

    Jonatan Hervoso1, W. Alexander Stinson1, Yuxuan Du2, Sarah Arwani1, Ellen Cealey1, David A. Fox1 and M. Asif Amin1, 1Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, 2Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, MI

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by inflammation and subsequent infiltration of peripheral blood monocytes (MNs) into the synovial tissue (ST). Micro (mi)RNAs are non-coding…
  • Abstract Number: 1367 • 2017 ACR/ARHP Annual Meeting

    Circulating Microbial Small RNAs Are Altered in Patients with Rheumatoid Arthritis

    Michelle J. Ormseth1, Shilin Zhao2, Ryan Allen2, Joseph F. Solus2, Quanhu Sheng2, Yan Guo2, Fei Ye2, Marisol Ramirez2, Kasey Vickers2 and C Michael Stein2, 1Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Small RNAs (sRNAs), such as microRNAs, are important regulators of biological processes and serve as important biomarkers of disease. We found that approximately half…
  • Abstract Number: 1710 • 2017 ACR/ARHP Annual Meeting

    Down-Regulation of microRNA-126 in Scleroderma Microvascular Endothelial Cells Enhances the Transition of Endothelial to Mesenchymal Cells (Endo-MT) Induced By TGFβ through Down-Regulating PI3/Akt Signaling Pathway By Targeting PIK3R2

    Yongqing Wang1, Shadia Nada2, Nezam Altorok2 and Bashar Kahaleh2, 1University of Toledo, Toledo, OH, 2Medicine/Rheumatology, University of Toledo, Toledo, OH

    Background/Purpose: The accumulation of myofibroblasts in fibrotic tissue plays an important role in the pathogenesis of scleroderma (SSc) fibrosis. Recent studies have shown that myofibroblasts…
  • Abstract Number: 1729 • 2017 ACR/ARHP Annual Meeting

    Increased Serum Levels of Micro-RNA 30d and Micro-RNA 423-5p in 2 Independent Cohorts of Patients with Morphea

    Jorre S. Mertens1,2, Wiola Marut1, Cornelis P.J. Bekker1, Elke M.G.J. de Jong3 and Timothy R.D.J. Radstake1,4, 1Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Dermatology, Radboud University Medical Center, Nijmegen, Netherlands, 3Radboud University Medical Center, Nijmegen, Netherlands, 4Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose : Morphea, also known as localized scleroderma, encompasses a group of idiopathic sclerotic skin diseases. MicroRNAs (miRNAs) are a large family of highly conserved…
  • Abstract Number: 1764 • 2017 ACR/ARHP Annual Meeting

    Small RNA Sequencing Shows Differential Plasma Microrna Expression in Patients with ANCA-Associated Vasculitis: A Pilot Study

    Kevin Byram1, Joseph F. Solus1, Quanhu Sheng1, Yan Guo1, C Michael Stein1 and Michelle J. Ormseth2, 1Vanderbilt University Medical Center, Nashville, TN, 2Rheumatology, Vanderbilt Medical Center, Nashville, TN

    Background/Purpose: MicroRNAs (miRNAs) are small RNA molecules (~22 nucleotides) that participate in post-transcriptional gene regulation. miRNAs have potential both as biomarkers for diagnosis and prognosis…
  • Abstract Number: 2150 • 2017 ACR/ARHP Annual Meeting

    Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease

    Yumiko Sugiyama, Ryusuke Yoshimi, Yosuke Kunishita, Daiga Kishimoto, Yohei Kirino and Hideaki Nakajima, Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Background/Purpose: Although intensive immunosuppressive treatment are necessary for the severe cases with polymyositis (PM)/dermatomyositis (DM), the prognostic factors or disease activity indices for PM/DM have…
  • Abstract Number: 2187 • 2017 ACR/ARHP Annual Meeting

    Association of Circulating microRNAs with Prevalent and Incident Osteoarthritis in Women: The Ofely Study

    Jean-Charles Rousseau1, Marjorie Millet1, Martine Croset1, Elisabeth Sornay-Rendu2, Olivier Borel2 and Roland Chapurlat3, 1INSERM 1033, Lyon, France, 2INSERM 1033, E. Herriot Hospital, Hospices Civils de Lyon, Lyon, France, 3INSERM 1033, University of Lyon, E. Herriot Hospital, Hospices Civils de Lyon, Lyon, France

    Background/Purpose: Sensitive and specific blood biomarkers to detect the initial stages of osteoarthritis (OA) and to predict the future development of the disease are not…
  • Abstract Number: 2326 • 2017 ACR/ARHP Annual Meeting

    Modeling Transcriptional Rewiring in Neutrophils through the Course of Treated Juvenile Idiopathic Arthritis

    Zihua Hu1, Kaiyu Jiang2, Mark B. Frank3, Yanmin Chen2 and James Jarvis4, 1Center for Computational Research, University at Buffalo, Buffalo, NY, 2Pediatrics, University at Buffalo, Buffalo, NY, 3Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Genetics, Genomics & Bioinformatics, University at Buffalo, Buffalo, NY

    Background/Purpose: We have previously shown that neutrophils in children with polyarticular juvenile idiopathic arthritis (JIA) display abnormal transcriptional patterns linked to fundamental metabolic derangements. These…
  • Abstract Number: 4 • 2017 ACR/ARHP Annual Meeting

    Downregulation of microRNAs in Plasmacytoid Dendritic Cells Is Associated with a Type I Interferon Signature in Systemic Lupus Erythematosus and Antiphospholipid Syndrome

    Lucas L. van den Hoogen1, Joel A.G. van Roon2,3, Ruth D.E. Fritsch-Stork4, Cornelis P.J. Bekker1, Aridaman Pandit1, Marzia Rossato5 and Timothy R.D.J. Radstake1, 1Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Laboratory for Translational immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Department of Rheumatology & Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: The most prominent alteration in the immune system of patients with SLE is a type I interferon (IFN) signature, which we recently also reported…
  • Abstract Number: 2338 • 2017 ACR/ARHP Annual Meeting

    Plasma Exosomes from Children with Juvenile Dermatomyositis Are Taken up By Human Aortic Endothelial Cells and Are Associated with Altered Gene Expression in Those Cells

    Kaiyu Jiang1, Zihua Hu2, Rie Karasawa3, Yanmin Chen1 and James Jarvis4, 1Pediatrics, University at Buffalo, Buffalo, NY, 2Center for Computational Research, University at Buffalo, Buffalo, NY, 3Institute of Medical Science, St. Marianna University School of Medicine, Japan, Kawasaki, Japan, 4Department of Genetics, Genomics & Bioinformatics, University at Buffalo, Buffalo, NY

    Background/Purpose: The pathology of juvenile dermatomyositis (JDM) is characterized by prominent vessel wall and perivascular inflammation. This feature of the disease has remained unexplained and…
  • Abstract Number: 138 • 2017 Pediatric Rheumatology Symposium

    Modeling Transcriptional Rewiring in Neutrophils through the Course of Treated Juvenile Idiopathic Arthritis

    Zihua Hu1, Kaiyu Jiang2, Mark B. Frank3, Yanmin Chen2 and James Jarvis4, 1Center for Computational Research, University at Buffalo, Buffalo, NY, 2Pediatrics, University at Buffalo, Buffalo, NY, 3Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY

    Background/Purpose: We have previously shown that neutrophils in children with polyarticular juvenile idiopathic arthritis (JIA) display abnormal transcriptional patterns linked to fundamental metabolic derangements. These…
  • Abstract Number: 1672 • 2016 ACR/ARHP Annual Meeting

    Microrna-29a Activation of Canonical Wnt Signaling By Targeting LRP6 in Ankylosing Spondylitis

    Jinxian Huang1, Zhihua Yin2, Zhongchao Fu3, Zhizhong Ye3 and Lijun Zhang4, 1Rheumatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China, 2Rheumatology, The Fourth People’s Hospital of Shenzhen, Shenzhen, China, 3The Fourth People’s Hospital of Shenzhen, Shenzhen, China, 4The University of Hong Kong-Shenzhen Hospital, Shenzhen, China

    Background/Purpose: Aberrant regulation of the Wnt pathway is a key element in the pathogenesis of Ankylosing spondylitis (AS). We previously found that miR-29a was significantly…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology